GGrantIndex
Sort

30,917 grants matching tumor microenvironment

Deciphering the Critical Determinants of Enteric and Tumor Niche Colonization by Microbes in Colorectal Cancer

$697,763
Christopher D Johnston · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA

Anti-CD38 targeted alpha emitter radioimmunotherapy to eliminate multiple myeloma

$697,579
Damian J. Green · Fred Hutchinson Cancer Research Center · R01 · FY2017 · CA

(PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast Cancer

$697,539
Anna Karolina Palucka · Jackson Laboratory · R01 · FY2017 · CA

A Unique Class of Reductively Activated Oncology Drugs

$697,415
Dale L Boger · Scripps Research Institute, The · R01 · FY2019 · CA

Vaccine and radiation for the therapy of human cancers

$697,290
James Hodge · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Vascularized Islet transplantation NICHE with local immunosuppression for the treatment of type 1 diabetes

$697,245
Alessandro Grattoni · Methodist Hospital Research Institute · R01 · FY2025 · DK

Leveraging fructose transport to create a privileged substrate to selectively fuel T cells

$697,232
Kayvan R Keshari · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA

Impact of Circulating Myeloid Cell Clusters on Anti-Tumor Immunity

$697,166
Sharon S Evans · Roswell Park Cancer Institute Corp · R01 · FY2025 · CA

Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancer

$696,801
Renier Joseph Brentjens · Roswell Park Cancer Institute Corp · U01 · FY2025 · CA

Leveraging fructose transport to create a privileged substrate to selectively fuel T cells

$696,769
Kayvan R Keshari · Sloan-Kettering Inst Can Research · R01 · FY2025 · CA

Targeting LCN2, a novel therapy for lung cancer

$696,569
Thales Papagiannakopoulos · New York University School Of Medicine · R01 · FY2025 · CA

Therapeutic targeting MDSC-mediated immune suppression in cancer

$696,515
Yulia Nefedova · Wistar Institute · R01 · FY2025 · CA

Targeting tumor-specific epitope for imaging and therapy for mesothelioma

$696,447
Jiang He · University Of Virginia · R01 · FY2025 · CA

Body composition and breast cancer survival: immune and metabolic biomarkers in breast tumors

$696,446
Elizabeth Marjorie Cespedes Feliciano · Kaiser Foundation Research Institute · R01 · FY2021 · CA

Role of the microbiota in regulating the mononuclear phagocyte system

$696,360
Silvana Goldszmid · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

Preclinical Testing of Targeted Therapies for Neurofibromas

$696,319
David W. Clapp · Indiana University Indianapolis · U01 · FY2009 · NS

TIMP-2-mediated Tumor Cell Differentiation and Chemo-sensitization Therapy

$696,022
William Stetler-Stevenson · Basic Sciences · Z01 · FY2007 · CA

A new mouse model for studying the pathogenesis and immunobiology of intrahepatic cholangiocarcinoma and improving its immunotherapy

$695,955
Michael Karin · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2025 · CA

Local microbiota signatures of pro-tumor immunity and checkpoint inhibition susceptibility in lung cancer

$695,920
Leopoldo Nicolas Segal · New York University School Of Medicine · R37 · FY2020 · CA

A personalized approach using hypoxia resolution to guide curative-intent radiation dose reduction to 30 Gy: A novel de-escalation paradigm for HPV-associated oropharynx cancers

$695,222
Nancy Y Lee · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA

Probabilistic Multiscale Modeling of the Tumor Microenvironment

$695,214
Wesley Tansey · Sloan-Kettering Inst Can Research · R37 · FY2025 · CA

Molecular Biomarkers in pathogenesis of Lymphangioleiomyomatosis (LAM)

$695,144
Jeanine M D'armiento · Columbia University Health Sciences · R01 · FY2024 · HL

Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122

$695,125
Antonio M Omuro · Yale University · R01 · FY2022 · CA

Project 1: Investigation of immune and stromal factors that promote prostate adenocarcinoma progression and castration response

$695,029
Charles L Sawyers · Columbia University Health Sciences · P01 · FY2022 · CA

Molecular Genomics Core

$694,781
Daniel Joseph Weisenberger · University Of Southern California · P30 · FY2025 · CA